Smital Shah
Director/Board Member presso PLIANT THERAPEUTICS, INC.
Patrimonio netto: 18 757 $ in data 31/03/2024
Profilo
Smital Shah is an Independent Director at Pliant Therapeutics, Inc. She previously served as an Independent Director at Graphite Bio, Inc. and as Treasurer at Gilead Sciences, Inc. from 2012 to 2014.
From 2018 to 2022, she held the position of Chief Financial & Business Officer at ProQR Therapeutics NV.
Ms. Shah holds an MBA from the University of California, Berkeley and the Haas School of Business.
She also has a graduate degree from Virginia Polytechnic Institute & State University and an undergraduate degree from the University of Mumbai.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
0.00% | 01/02/2024 | 840 ( 0.00% ) | 18 757 $ | 31/03/2024 |
| 07/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Smital Shah
| Società | Posizione | Inizio |
|---|---|---|
| PLIANT THERAPEUTICS, INC. | Director/Board Member | 14/03/2019 |
Precedenti posizioni note di Smital Shah
| Società | Posizione | Fine |
|---|---|---|
| PROQR THERAPEUTICS N.V. | Director of Finance/CFO | 01/10/2022 |
| GILEAD SCIENCES, INC. | Treasurer | 01/09/2014 |
| LENZ THERAPEUTICS, INC. | Director/Board Member | - |
Formazione di Smital Shah
| Virginia Polytechnic Institute & State University | Graduate Degree |
| University of Mumbai | Undergraduate Degree |
| Haas School of Business | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| PROQR THERAPEUTICS N.V. | Health Technology |
| PLIANT THERAPEUTICS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Graphite Bio, Inc.
 Graphite Bio, Inc. BiotechnologyHealth Technology Graphite Bio, Inc. is a clinical-stage gene editing company. It engages in the business of developing therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo on June 1, 2017 and is headquartered in South San Francisco, CA. | Health Technology |
- Borsa valori
- Insiders
- Smital Shah
